ReviewPLoS neglected tropical diseases2021
Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.
Review in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Flavonoids in the treatment ofFrontiers in pharmacology · 2025Pooled it
- Improved Treatment Outcome Following the Use of a Wound Dressings in Cutaneous Leishmaniasis Lesions.Pathogens (Basel, Switzerland) · 2024Trial
- Optimisation of a Topical Miltefosine Carbopol-Based Gel for Cutaneous Leishmaniasis: Antileishmanial Activity After Storage and Drug Response.Gels (Basel, Switzerland) · 2026Article
- Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis.International journal of molecular sciences · 2026Article
- Development of a 17-DMAG-Loaded Carboxymethylcellulose Gel forACS omega · 2026Article
- Cutaneous leishmaniasis of the nose evaluated with confocal microscopy successfully treated with topical 5% imiquimod.JAAD case reports · 2026Article
- Tri-Layer Composite Nanofiber Wound Dressing Incorporating Glucantime and Silver Nanoparticles for Cutaneous Leishmaniasis Management.Journal of functional biomaterials · 2026Article
- Enhanced Topical Treatment of Cutaneous Leishmaniasis Using Niosomal Gel of Tioxolone-Benzoxonium Chloride: In silico, in vitro, and in vivo Evaluation.Research and reports in tropical medicine · 2026Article
- The Safety and Efficacy of an Immunomodulator Garlic-Based Cream (LeishG1) for Treating Uncomplicated Cutaneous Leishmaniasis: A Single-Blind, Multi-Center Study.Health science reports · 2025Article
- Molecular profiling and risk factors assessment of cutaneous leishmaniasis in an expanding endemic focus of Punjab, Pakistan.Parasitology research · 2025Article
- Complete Resolution of Cutaneous Leishmaniasis With a Novel Topical Combination Therapy: A Case Series.Clinical case reports · 2025Article
- Trivalent and Pentavalent Antimonials Impair Cardiac Mitochondrial Function in Mice.International journal of molecular sciences · 2025Article
- Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action.ACS omega · 2025Review
- Comparative Gut Proteome ofMicroorganisms · 2025Article
- Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises.Clinics and practice · 2025Review
- A novel inhibitory strategy ofFuture microbiology · 2025Article
- Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model.Marine drugs · 2024Article
- Therapeutic effect of topical tamoxifen in murine cutaneous leishmaniasis caused byAntimicrobial agents and chemotherapy · 2024Article
- Epidemiology and future risk estimates of cutaneous leishmaniasis in district Dera Ismail Khan, Pakistan: analysis of data from 2019-2022.African health sciences · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide specially in developing and underdeveloped countries. There are 2 major types of cutaneous leishmaniasis based on the causating species found in different regions of the world. These include New and Old World cutaneous leishmaniasis, which are self-healing, but if not treated, these may cause severe scars and many other complications like mucosal involvement. The conventional gold standard treatment for both types is mainly intralesional or parenteral administration of antimonial. Lately, a great deal of research has been done on development of topical treatment based on single agent or combination therapy. This review summarizes the current state of literature regarding therapeutic outcome of topical treatment against cutaneous leishmaniasis caused by different species in different regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.